skip to main content

United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008

SILVER SPRING, Md., Feb. 12 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2007 fourth quarter and annual financial results before the open of market on Tuesday, February 19, 2008.

United Therapeutics will host a half-hour teleconference on Tuesday, February 19, 2008, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 800-603-1777, with international callers dialing +1-706- 679-8129. A rebroadcast of the teleconference will be available for one week following the teleconference by dialing 800-642-1687, with international callers dialing +1-706-645-9291, and using the conference call identification number 33422885.

United Therapeutics' 2008 Annual Meeting of stockholders will be held on April 29, 2008, at the company's headquarters located at 1110 Spring Street, Silver Spring, Maryland 20910. Only stockholders of record at the close of business on March 7, 2008, will be entitled to notice of and to vote at the 2008 Annual Meeting. United Therapeutics' proxy materials regarding the 2008 Annual Meeting will be filed with the Securities and Exchange Commission on or about March 7, 2008.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g]

SOURCE United Therapeutics Corporation

Contact: Andrew Fisher of United Therapeutics Corporation, +1-202-483-7000, [email protected]

Recent Press Releases

Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next yearSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr.Martine Rothblatt,Chairperson and Chief Executive Officer, will provide a...
The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly pre-treated patients with...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz,President and Chief Operating Officer, will provide a company...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before...